Smith covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Roche Holding AG. According to TipRanks, Smith has an average return of 9.9% and a 61.86% success rate on recommended stocks.
Lonza Group Ltd has an analyst consensus of Strong Buy, with a price target consensus of CHF690.50, implying a 26.00% upside from current levels. In a report released on July 23, Goldman Sachs also maintained a Buy rating on the stock with a CHF680.00 price target.
Based on Lonza Group Ltd’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of CHF3.37 billion and a net profit of CHF591 million. In comparison, last year the company earned a revenue of CHF3.58 billion and had a net profit of CHF426 million
